Sagimet Biosciences Enters New Sales Agreement with Leerink

Sagimet Biosciences, Inc. Class A ( (SGMT) ) has issued an update.

Sagimet Biosciences Inc. announced on August 14, 2025, that it has entered into a Sales Agreement with Leerink Partners LLC to offer and sell up to $75 million worth of its Series A common stock through at-the-market offerings. The company has the flexibility to suspend or terminate the agreement at any time and has also terminated its previous sales agreement with Cantor Fitzgerald & Co., under which no shares were sold from August 15, 2024, to August 14, 2025.

The most recent analyst rating on (SGMT) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Sagimet Biosciences, Inc. Class A stock, see the SGMT Stock Forecast page.

Spark’s Take on SGMT Stock

According to Spark, TipRanks’ AI Analyst, SGMT is a Neutral.

Sagimet Biosciences’ overall score reflects substantial financial difficulties marked by persistent losses and reliance on external funding. While technical indicators show short-term bullish momentum, the lack of profitability and negative equity pose significant long-term risks. Valuation metrics further highlight the challenges in viewing this stock as an attractive investment.

To see Spark’s full report on SGMT stock, click here.

More about Sagimet Biosciences, Inc. Class A

Average Trading Volume: 1,587,462

Technical Sentiment Signal: Strong Buy

Current Market Cap: $292.9M

See more insights into SGMT stock on TipRanks’ Stock Analysis page.